Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

Bruker Corporation

BRKRNASDAQEQUITYCurrent

Annual Report

Filed Mar 3, 2025Accepted Mar 3, 2025, 4:27 PM ESTCIK 1109354Accession 0000950170-25-030897
Share

Company context

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, clinical microbiology and molecular diagnostics, as well as in the semiconductor industry. For more information, please visit www.bruker.com.

Current securities

Recent company filings

  1. 144 filingSep 15, 2026
  2. 4 filingAug 18, 2026
  3. 4 filingAug 18, 2026
  4. 144 filingAug 17, 2026
  5. 144 filingAug 14, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗